Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
Accolade, Inc. (Nasdaq: ACCD) is a pioneering Personalized Healthcare company devoted to providing exceptional healthcare experiences to millions of people and their families, enabling them to live their healthiest lives. Accolade's range of solutions targets employers, health plans, and consumers by integrating virtual primary care, mental health services, expert medical opinions, and top-tier care navigation. Their innovative platform leverages cloud-based intelligent technology, coupled with expert clinical teams, including registered nurses, physician medical directors, pharmacists, and primary care physicians, to deliver comprehensive advocacy and healthcare services.
The company has been recognized for its significant contributions to the healthcare industry, such as being named one of Forbes' 25 most promising companies and achieving a spot on Inc. 500's list of America's fastest-growing private companies. Accolade's mission is to guide individuals through the complexities of the healthcare system, thereby enhancing outcomes and reducing costs for employers and health plans.
Accolade has recently gained considerable attention for its impressive 227% revenue growth, attributed to a relentless focus on delivering exceptional outcomes. This achievement earned Accolade a place in the Deloitte Technology Fast 500™ list for 2023. CEO Rajeev Singh credits the company's innovative approach and dedicated team for this remarkable performance.
Accolade's Trusted Partner Ecosystem, launched in 2019, exemplifies its commitment to comprehensive healthcare solutions. This ecosystem includes partnerships with leading companies like Kindbody and Noom, expanding access to specialized services such as fertility and metabolic health.
Accolade's financial health remains robust, with recent quarterly results showcasing a significant reduction in net loss and positive adjusted EBITDA, indicating a promising trajectory toward sustainable growth and profitability.
With a consumer satisfaction rating consistently over 90%, Accolade is steadily advancing its vision of transforming healthcare through predictive engagement, proactive care, and by addressing barriers to access and continuity of care. The company's forward-thinking approach ensures it remains at the forefront of healthcare innovation, making a significant impact on the industry and the lives of the people it serves.
For more information, visit accolade.com.
Transcarent and Accolade (NASDAQ:ACCD) announced the expiration of the Hart-Scott-Rodino waiting period for their pending merger, marking a significant milestone toward completing their transaction. The merger is expected to close in Q2 2025, subject to Accolade stockholder approval and other customary conditions.
The combination aims to integrate Transcarent's AI-powered WayFinding solution and comprehensive care experiences with Accolade's advocacy, expert medical opinions, and primary care services. The merger will create a platform focused on improving healthcare access and decision-making for consumers.
Evercore serves as Transcarent's financial advisor, while Morgan Stanley & Co advises Accolade. The deal brings together two companies focused on delivering high-quality, affordable healthcare solutions through a combination of technology and human support.
Transcarent has announced its acquisition of Accolade (NASDAQ:ACCD) for $7.03 per share in cash, representing a total equity value of approximately $621M. The deal, unanimously approved by both companies' boards, represents a 110% premium over Accolade's closing price on January 7, 2025.
The combined platform will integrate Transcarent's generative AI-powered WayFinding and comprehensive care experiences with Accolade's Personalized Healthcare Platform, advocacy, expert medical opinions, and primary care services. The merger will create an industry-leading platform serving over 1,400 employer and payer clients.
The transaction is expected to close during the second quarter of 2025, subject to Accolade stockholder approval and regulatory approvals. Upon completion, Accolade will become private and delist from Nasdaq. The company expects to report Q3 fiscal 2025 results within previously provided guidance but has withdrawn future financial guidance due to the acquisition.
Accolade (NASDAQ: ACCD) announced that its virtual healthcare service PlushCare now accepts Medicare Part B coverage, extending access to 64 million beneficiaries across all 50 states. The expansion provides primary care, clinical weight management, and mental health support services to older adults and individuals with disabilities or chronic conditions.
The initiative addresses significant healthcare barriers, particularly relevant as approximately 5.8 million Americans face difficulties accessing medical care, and 21% of adults aged 65+ experience mobility disabilities. PlushCare's platform enables diagnosis and treatment of over 6,800 medical conditions, allowing patients to choose their preferred healthcare providers while receiving care from home.
This expansion aligns with recent legislative developments that extended Medicare telehealth waivers until March 31, 2025, emphasizing virtual care's role in healthcare accessibility.
Transcarent has announced the acquisition of Accolade (NASDAQ:ACCD) for $7.03 per share in cash, representing a total equity value of approximately $621M. The deal offers a 110% premium over Accolade's closing price on January 7, 2025.
The combined platform will integrate Transcarent's generative AI-powered WayFinding and comprehensive care experiences with Accolade's Personalized Healthcare Platform, advocacy, expert medical opinions, and primary care services. The merger will serve more than 1,400 employer and payer clients.
The transaction, unanimously approved by both companies' Boards of Directors, is expected to close during the second calendar quarter of 2025, subject to Accolade stockholder approval and regulatory approvals. The deal will be financed through equity funding led by General Catalyst and Glen Tullman's 62 Ventures. Upon completion, Accolade will become private and delist from Nasdaq.
Accolade (NASDAQ: ACCD) has announced it will release its fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after market close. The company will host a conference call to discuss the results at 4:30 p.m. E.T. on the same day. Pre-registration is required for telephone access, and participants will receive dial-in details upon registration. The call will also be accessible via live audio webcast on the company's investor relations website. A replay will be available for one year on the same platform.
Accolade (NASDAQ: ACCD) has announced its participation in three upcoming investor conferences. The company will present at the Stephens Annual Investment Conference in Nashville on November 20 at 9:00 am CT, attend the CG MedTech, Diagnostics and Digital Health & Services Forum in New York on November 21 (for one-on-one meetings only), and present at the Piper Sandler 36th Annual Healthcare Conference in New York on December 5 at 10:00 am ET. Webcasts will be available at ir.accolade.com with replays accessible for 90 days, except for the CG MedTech event which will not be webcast.
Accolade, Inc. (Nasdaq: ACCD) has announced a partnership with Renalogic, a leader in managing chronic kidney disease (CKD) costs for self-insured employers. Renalogic will join Accolade's Trusted Partner Ecosystem, offering CKD risk management and dialysis cost containment solutions. This partnership aims to address the rising health costs for employers, particularly the high expenses associated with late-stage CKD and dialysis.
Renalogic's services include:
- ImpactIQ: Data algorithms to identify diagnosed and undiagnosed CKD members
- ImpactAdvocate: Support to delay end-stage renal disease and manage dialysis starts
- ImpactProtect: Advising on fair market rates for dialysis services
The partnership is expected to drive cost savings for customers while improving health outcomes for CKD members. Accolade and Renalogic will provide integrations to joint customers at no additional cost, including warm handoffs from Accolade Care Advocates to Renalogic's clinical team.
Accolade (NASDAQ: ACCD) announced financial results for fiscal Q2 2025 ended August 31, 2024. Revenue increased 10% to $106.4 million, while net loss improved 27% to $23.9 million. Non-GAAP Adjusted EBITDA loss narrowed 68% to $2.8 million, and Adjusted Gross Margin expanded to 47.3%.
CEO Rajeev Singh stated that Accolade is positioned to deliver its first full year of Adjusted EBITDA profitability and positive cash flow. The company focuses on solving the Physician Gap through a physician-led advocacy approach. CFO Steve Barnes highlighted Accolade's execution in delivering profitable growth, with the net cash position improving by over $20 million compared to convertible debt in the past year.
Accolade, Inc. (NASDAQ: ACCD) has announced the release date for its fiscal second quarter 2025 financial results. The company will disclose the results on Tuesday, October 8, 2024, before market open. Following the release, Accolade will host a conference call at 8:00 a.m. E.T. to review the results.
Interested parties can participate in the conference call via telephone by pre-registering through a provided link. Upon registration, participants will receive dial-in information and a unique PIN. Alternatively, a live audio webcast of the call will be accessible online at the company's investor relations website. For those unable to attend live, a replay of the call will be available for one year via webcast on the same website.
Accolade (NASDAQ: ACCD) has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for Thursday, September 5 at 9:15 am ET in New York. Investors and interested parties can access a live webcast of the presentation through Accolade's investor relations website at ir.accolade.com. For those unable to attend or watch live, a replay of the presentation will be available on the same platform for 90 days following the event. This conference provides Accolade with an opportunity to showcase its healthcare technology solutions to a global audience of investors and industry professionals.
FAQ
What is the current stock price of Accolade (ACCD)?
What is the market cap of Accolade (ACCD)?
What does Accolade, Inc. do?
How has Accolade performed financially recently?
What is the Trusted Partner Ecosystem?
Who are Accolade's key partners?
What recognition has Accolade received?
What is Accolade's mission?
How does Accolade contribute to healthcare cost reduction?
How does Accolade engage with its members?
What is Accolade's customer satisfaction rating?
Where can I find more information about Accolade?
